Related Experiment Video
Updated: Jan 9, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Dermal Glucose Sensing has a Shorter Time Lag Relative to Blood Glucose: Implications for Hypoglycemia Detection and
Khadije Ahmad1, Peter Rule1, Brianna Bañez1
1Laxmi Therapeutic Devices, Goleta, CA, USA.
Introduction:
Current continuous glucose monitors (CGM) sensing glucose in the subcutaneous tissue have a significant time lag (τ). This delay could result in severe hypo/hyperglycemia and lower time in range (TIR). Dermal sensing can greatly reduce time lag.
Methods:
In a clinical study conducted at two US-based clinical centers, subjects with type 1 diabetes mellitus (DM) wore a novel dermal CGM + Abbott-Libre 3 or Dexcom-G7. All were compared to a YSI-glucose analyzer. Time lag kinetics for all sensors were modeled using the two-compartment model and compared to published data. Time lag data and its potential effect on TIR were also analyzed.
Results:
Data from 55 subjects showed fast kinetics for the dermal CGM. In total, 93% of the Laxmi sensors had a τ of 0-2 minutes, whereas commercial CGMs had a varying distribution of τ (-10 to 10+ minutes). This reduction in τ by 10 minutes has profound effects on errors in insulin administration in both open-loop and in a proportional-integral-derivative (PID) model of automated insulin delivery (AID). To evaluate the effect of tau on TIR, we used an in silico PID controller in a well-accepted model (UVA type 1 diabetes simulator) over a variety of conditions. We observed that tau greatly affects TIR and the distribution of the time out of range parameters.
Conclusion:
Dermal sensing has a time lag close to 0. Individuals with DM can have lower glucose targets with a system that eliminates fear of hypoglycemia, resulting in higher TIR and better control of DM.
Related Concept Videos
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Type 2 and Gestational

